340B Providers Offer Varying Approaches To Tracking, Using Discounts At Hearing
House Energy and Commerce Committee Chair Greg Walden, R-Ore., expresses frustration at lack of reliable data on the way providers account for 340B drug discounts at Oct. 11 hearing.
You may also be interested in...
House Energy & Commerce Committee recommends more oversight of hospital participation in the 340B drug discount program.
PhRMA is stepping up its advocacy for 340B reform, noting recent reduction in Medicare payments for 340B is encouraging in that it indicates Administration may be open to further change.
There appears to be bipartisan interest in beefing up HRSA’s ability to oversee the 340B program – but the next step is likely to be more hearings and fact-finding, not immediate legislative changes.